The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells

Issam Ben Sahra; Jean François Tanti; Frédéric Bost

doi:10.4161/auto.6.5.12434

The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells

Issam Ben Sahra, Jean François Tanti, Frédéric Bost^*

^*Corresponding author for this work

Biochemistry and Molecular Genetics

Research output: Contribution to journal › Short survey › peer-review

100 Scopus citations

Abstract

Targeting cancer cell metabolism is a promising new strategy to fight cancer. Metformin, a widely used antidiabetic agent, and 2-deoxyglucose (2DG) drastically affect cancer cell metabolism. Recently, we showed that the combination of the two drugs was much more harmful for cancer cells than the treatment with metformin or 2DG alone. At the cellular level, this combination leads to p53- and AMPK-dependent apoptosis. Furthermore, we showed that metformin inhibits 2DG-induced autophagy, decreases beclin 1 expression and triggers a switch from a survival process to cell death.

Original language	English (US)
Pages (from-to)	670-671
Number of pages	2
Journal	Autophagy
Volume	6
Issue number	5
DOIs	https://doi.org/10.4161/auto.6.5.12434
State	Published - Jul 1 2010

Keywords

2 deoxyglucose
AMPK
Apoptosis
Autophagy
Metabolism
Metformin
P53
Prostate cancer

ASJC Scopus subject areas

Molecular Biology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4161/auto.6.5.12434

Cite this

@article{aca0fc0bfc5b4f389a10ba698c5f944c,

title = "The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells",

abstract = "Targeting cancer cell metabolism is a promising new strategy to fight cancer. Metformin, a widely used antidiabetic agent, and 2-deoxyglucose (2DG) drastically affect cancer cell metabolism. Recently, we showed that the combination of the two drugs was much more harmful for cancer cells than the treatment with metformin or 2DG alone. At the cellular level, this combination leads to p53- and AMPK-dependent apoptosis. Furthermore, we showed that metformin inhibits 2DG-induced autophagy, decreases beclin 1 expression and triggers a switch from a survival process to cell death.",

keywords = "2 deoxyglucose, AMPK, Apoptosis, Autophagy, Metabolism, Metformin, P53, Prostate cancer",

author = "Sahra, {Issam Ben} and Tanti, {Jean Fran{\c c}ois} and Fr{\'e}d{\'e}ric Bost",

note = "Funding Information: We thank Y. Le Marchand Brustel for carefully reading the manuscript. This research was supported by INSERM, University of Nice Sophia-Antipolis, Association pour la Recherche sur le Cancer (grant# 1018), and the Minist{\`e}re de la Recherche (IBS). F. Bost and J.F. Tanti are CNRS investigators.",

year = "2010",

month = jul,

day = "1",

doi = "10.4161/auto.6.5.12434",

language = "English (US)",

volume = "6",

pages = "670--671",

journal = "Autophagy",

issn = "1554-8627",

publisher = "Landes Bioscience",

number = "5",

}

TY - JOUR

T1 - The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells

AU - Sahra, Issam Ben

AU - Tanti, Jean François

AU - Bost, Frédéric

N1 - Funding Information: We thank Y. Le Marchand Brustel for carefully reading the manuscript. This research was supported by INSERM, University of Nice Sophia-Antipolis, Association pour la Recherche sur le Cancer (grant# 1018), and the Ministère de la Recherche (IBS). F. Bost and J.F. Tanti are CNRS investigators.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Targeting cancer cell metabolism is a promising new strategy to fight cancer. Metformin, a widely used antidiabetic agent, and 2-deoxyglucose (2DG) drastically affect cancer cell metabolism. Recently, we showed that the combination of the two drugs was much more harmful for cancer cells than the treatment with metformin or 2DG alone. At the cellular level, this combination leads to p53- and AMPK-dependent apoptosis. Furthermore, we showed that metformin inhibits 2DG-induced autophagy, decreases beclin 1 expression and triggers a switch from a survival process to cell death.

AB - Targeting cancer cell metabolism is a promising new strategy to fight cancer. Metformin, a widely used antidiabetic agent, and 2-deoxyglucose (2DG) drastically affect cancer cell metabolism. Recently, we showed that the combination of the two drugs was much more harmful for cancer cells than the treatment with metformin or 2DG alone. At the cellular level, this combination leads to p53- and AMPK-dependent apoptosis. Furthermore, we showed that metformin inhibits 2DG-induced autophagy, decreases beclin 1 expression and triggers a switch from a survival process to cell death.

KW - 2 deoxyglucose

KW - AMPK

KW - Apoptosis

KW - Autophagy

KW - Metabolism

KW - Metformin

KW - P53

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=77955458963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955458963&partnerID=8YFLogxK

U2 - 10.4161/auto.6.5.12434

DO - 10.4161/auto.6.5.12434

M3 - Short survey

C2 - 20559023

AN - SCOPUS:77955458963

SN - 1554-8627

VL - 6

SP - 670

EP - 671

JO - Autophagy

JF - Autophagy

IS - 5

ER -

The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this